https://www.genengnews.com/topics/genome-editing/stockwatch-cgt-stocks-fall-on-fda-therapeutic-products-upheaval/?utm_content=336301471&utm_medium=social&utm_source=twitter&hss_channel=tw-31484145
One of the reasons the share price has taken a bit of a hit recently is due to Nicole Verdun put on extended leave. I think relationships with FDA and there policy matters in approvals and most of the cell and gene therapy stocks have corrected after the above event. I believe this is a short term blip in the long term story of mesoblast and in the long run wont matter.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.030(1.85%) |
Mkt cap ! $2.108B | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.67 | $1.63 | $4.884M | 2.962M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10583 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 16415 | 4 |
View Market Depth
| Last trade - 16.12pm 27/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |